EP4251633A4 - Inhibiteurs de cd73 et leurs utilisations pharmaceutiques - Google Patents

Inhibiteurs de cd73 et leurs utilisations pharmaceutiques Download PDF

Info

Publication number
EP4251633A4
EP4251633A4 EP21896011.0A EP21896011A EP4251633A4 EP 4251633 A4 EP4251633 A4 EP 4251633A4 EP 21896011 A EP21896011 A EP 21896011A EP 4251633 A4 EP4251633 A4 EP 4251633A4
Authority
EP
European Patent Office
Prior art keywords
inhibitors
pharmaceutical uses
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21896011.0A
Other languages
German (de)
English (en)
Other versions
EP4251633A1 (fr
Inventor
Yuhua Zhang
Chuanhao HUANG
Xianqi Kong
Gang Chen
Jiasheng LU
Qiguo Zhang
Dawei Chen
Xingwu ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Risen Suzhou Pharma Tech Co Ltd
Original Assignee
Risen Suzhou Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/133,348 external-priority patent/US11530234B2/en
Application filed by Risen Suzhou Pharma Tech Co Ltd filed Critical Risen Suzhou Pharma Tech Co Ltd
Publication of EP4251633A1 publication Critical patent/EP4251633A1/fr
Publication of EP4251633A4 publication Critical patent/EP4251633A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP21896011.0A 2020-11-25 2021-11-25 Inhibiteurs de cd73 et leurs utilisations pharmaceutiques Withdrawn EP4251633A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011346141 2020-11-25
US17/133,348 US11530234B2 (en) 2018-09-11 2020-12-23 CD73 inhibitors and pharmaceutical uses thereof
PCT/CA2021/051688 WO2022109741A1 (fr) 2020-11-25 2021-11-25 Inhibiteurs de cd73 et leurs utilisations pharmaceutiques

Publications (2)

Publication Number Publication Date
EP4251633A1 EP4251633A1 (fr) 2023-10-04
EP4251633A4 true EP4251633A4 (fr) 2024-09-25

Family

ID=81753702

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21896011.0A Withdrawn EP4251633A4 (fr) 2020-11-25 2021-11-25 Inhibiteurs de cd73 et leurs utilisations pharmaceutiques

Country Status (5)

Country Link
EP (1) EP4251633A4 (fr)
CN (1) CN116546990A (fr)
AU (1) AU2021389685A1 (fr)
CA (1) CA3200232A1 (fr)
WO (1) WO2022109741A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025260011A1 (fr) * 2024-06-14 2025-12-18 Alnylam Pharmaceuticals, Inc. Monomères modifiés en 5', oligonucléotides et arn double brin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200078388A1 (en) * 2018-09-11 2020-03-12 Risen (Suzhou) Pharma Tech Co. Ltd. Cd73 inhibitors and pharmaceutical uses thereof
WO2020051686A1 (fr) * 2018-09-11 2020-03-19 Risen (Suzhou) Pharma Tech Co. Ltd. Inhibiteurs de cd73 et utilisations pharmaceutiques associées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2225229A1 (fr) * 2007-11-26 2010-09-08 Pfizer Inc. Dérivés de pyrazole comme inhibiteurs de 5-lo
WO2017120508A1 (fr) * 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulateurs de l'ecto-5 '-nucléotidase et leur utilisation
WO2018094148A1 (fr) * 2016-11-18 2018-05-24 Arcus Biosciences, Inc. Inhibiteurs de l'immunosuppression médiée par cd73
IL304348B2 (en) * 2018-04-30 2024-08-01 Oric Pharmaceuticals Inc CD73 inhibitors
CN114539340B (zh) * 2020-11-25 2024-06-07 润佳（苏州）医药科技有限公司 Cd73抑制剂及其药学应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200078388A1 (en) * 2018-09-11 2020-03-12 Risen (Suzhou) Pharma Tech Co. Ltd. Cd73 inhibitors and pharmaceutical uses thereof
WO2020051686A1 (fr) * 2018-09-11 2020-03-19 Risen (Suzhou) Pharma Tech Co. Ltd. Inhibiteurs de cd73 et utilisations pharmaceutiques associées

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022109741A1 *

Also Published As

Publication number Publication date
CN116546990A (zh) 2023-08-04
CA3200232A1 (fr) 2022-06-02
WO2022109741A1 (fr) 2022-06-02
EP4251633A1 (fr) 2023-10-04
AU2021389685A9 (en) 2024-02-08
AU2021389685A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
EP4215208A4 (fr) Association pharmaceutique et son utilisation
EP3849992A4 (fr) Inhibiteurs de cd73 et utilisations pharmaceutiques associées
CA3265870A1 (fr) Compositions pharmaceutiques à base d'inhibiteurs de la topoisomérase-1 dérivés de l'exatécan, et leurs utilisations
EP3960741A4 (fr) Composés de quinoléine et compositions pharmaceutiques et leurs utilisations
EP3843742A4 (fr) Inhibiteurs de cd73 et leurs utilisations thérapeutiques
EP4251633A4 (fr) Inhibiteurs de cd73 et leurs utilisations pharmaceutiques
EP4330228A4 (fr) Inhibiteurs de g-alpha-s et leurs utilisations
EP4364735A4 (fr) Composition pharmaceutique et son utilisation
EP4319740A4 (fr) Inhibiteur d'urat1, compositions pharmaceutiques et leurs utilisations
EP4342492A4 (fr) Combinaison pharmaceutique et son utilisation
EP4129282A4 (fr) Association pharmaceutique et son utilisation
EP3967693A4 (fr) Inhibiteur pi3k amorphe et composition pharmaceutique le comprenant
HK40076361A (en) Aspacytarabine pharmaceutical compositions and uses thereof
EP4100020A4 (fr) Compositions pharmaceutiques d'aspacytarabine et leurs utilisations
HK40114337A (en) Irhom2 inhibitors and uses thereof
HK40108347A (en) Inhibitors and uses thereof
HK40107944A (en) Urat1 inhibitor, pharmaceutical compositions and uses thereof
EP4125873A4 (fr) Compositions pharmaceutiques et utilisation de celles-ci
HK40085903A (en) Zbtb32 inhibitors and uses thereof
HK40099664A (en) Pharmaceutical composition and use thereof
HK40082856A (en) Inhibitors and uses thereof
HK40111933A (en) Rock2 inhibitors and uses thereof
CA3307498A1 (fr) Compositions pharmaceutiques et leurs utilisations
HK40105811A (en) Tyk2 inhibitors and uses thereof
HK40105803A (en) Tyk2 inhibitors and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230623

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240822

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20240817BHEP

Ipc: A61K 31/7076 20060101ALI20240817BHEP

Ipc: A61K 45/06 20060101ALI20240817BHEP

Ipc: C07H 19/20 20060101AFI20240817BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RISEN (SUZHOU) PHARMA TECH CO., LTD.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20260204